Newswire (Published: Tuesday, July 4, 2017, Received: Thursday, June 29, 2017, 1:23:20 PM CDT)
Word Count: 531
Research Conducted at Department of Urology Has Updated Our Knowledge about Prostate Cancer (Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, ...)
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Barcelona, Spain, by NewsRx editors, research stated, "The effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in prostate cancer (PCa) patients is not well understood. We evaluated changes in CP after 6 months of medical castration with luteinizing hormone-releasing hormone (LHRH) analogues."
Our news journalists obtained a quote from the research from the Department of Urology, "We performed a prospective, observational, multicenter, open-label study of PCa patients scheduled to receive LHRH analogues for >= 6 months. We assessed 4 domains of CP at baseline and after 6 months of ADT: (1) working memory, assessed with the Wechsler Adult Intelligence Scale III (WAIS III) Digit Span subtest; (2) visual memory, assessed with an ad hoc visual memory test; (3) visuospatial ability, assessed with the Judgment of Line Orientation test and Mental Rotation of Three-Dimensional Objects test; and (4) nonverbal analytical reasoning, assessed with the WAIS III Matrix Reasoning test. Changes outside the baseline 95% confidence intervals were considered significant. A total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test whereas 63 (20.4%) experienced significant changes on >= 1 test. Most of these patients showed a change on only 1 test, distributed evenly between improvement (58 patients, 18.8%) and worsening (56 patients, 18.2%). For individual tests, most patients (87.8%-91.8%) had no change from baseline; however, the significant changes (improvement vs deterioration) were as follows: WAIS III Digit Span subtest (6.3% vs 5.9%), visual memory (5.3% vs 5.7%), Judgment of Line Orientation test (5.3% vs 4.5%), Mental Rotation of Three-Dimensional Objects test (4.1% vs 4.1%), and WAIS III Matrix Reasoning test (4.8% vs 5.8%)."
According to the news editors, the research concluded: "CP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration."
For more information on this research see: Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2017;98(3):590-594. International Journal of Radiation Oncology Biology Physics can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Oncology - Prostate Cancer).
Our news journalists report that additional information may be obtained by contacting J. Morote, Hosp Univ Vall DHebron, Dept. of Urol, Barcelona, Spain. Additional authors for this research include A.J. Tabernero, J.L.A. Ossorio, J.P. Ciria, J.L. Dominguez-Escrig, F. Vazquez, J. Angulo, F.J. Lopez, R. de La Iglesia and J. Romero.
Keywords for this news article include: Barcelona, Spain, Europe, Pituitary Gonadotropins, Luteinizing Hormone, Prostatic Neoplasms, Pituitary Hormones, Peptide Proteins, Peptide Hormones, Prostate Cancer, Oncology, Department of Urology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Province of Barcelona
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices